RxDoctor Payments Data

Edwardo Verzola, MD

Gastroenterology · Festus, MONPI 1245381201

Payments from drug & device makers

$1,267in general payments, 2019–2025

Across 72 payments — averaging $17.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$299
  • Takeda Pharmaceuticals U.S.A., Inc.$195
  • AbbVie$195
  • Phathom Pharmaceuticals, Inc.$119
  • Pfizer$53
  • QOL Medical, LLC$49
  • plus $357 from 13 others

What the payments were for

  • Food & beverage$1,267100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,267 in reported general payments places this provider in the 45th percentile of 374 gastroenterology providers in Missouri.

See all gastroenterology providers in Missouri

Medicare billing

Part B allowed, 2024
$78,238
Medicare patients
377
Services billed
669

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin13$38,927
LinzessLinaclotide44$30,703
CreonLipase/Protease/Amylase12$28,814
ViberziEluxadoline11$20,933
TrulancePlecanatide21$14,256
MotegrityPrucalopride Succinate14$7,465
SutabSod Sulf/Pot Chloride/Mag Sulf36$5,861
Dexlansoprazole DrDexlansoprazole13$5,634
Pantoprazole Sodium381$3,992
Colestipol Hcl35$2,507
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl140$1,883
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl112$1,604
Omeprazole68$1,002
Ursodiol14$985
Esomeprazole Magnesium40$688

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon, Viberzi$195$80,45067 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$299$53,18234 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$195$7,46514 claims
Braintree Laboratories, Inc.Sutab$34$5,86136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 374 gastroenterology providers in Missouri.

Other gastroenterology in Festus

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →